Can earlier biomarker measurements explain a treatment effect on diabetes incidence? A robust comparison of five surrogate markers

Surrogate Endpoints in Clinical Trials

(2023) Michael R. Elliott   Annual Review of Statistics and Its Application

FDA’s dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps

(2022) John G Rizk et al.   BMJ Evidence-Based Medicine

FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway

(2021) Elisabeth Mahase   BMJ-British Medical Journal

Testing for heterogeneity in the utility of a surrogate marker

(2021) Layla Parast et al.   BIOMETRICS

The triglyceride–glucose index is a more powerful surrogate marker for predicting the prevalence and incidence of type 2 diabetes mellitus than the homeostatic model assessment of insulin resistance

(2021) Hye Min Park et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

A Comprehensive Update on the Chylomicronemia Syndrome

(2020) Ronald B. Goldberg et al.   Frontiers in Endocrinology

Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide

(2019) Till Sprenger et al.   Multiple Sclerosis Journal

Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker

(2019) Xuan Wang et al.   BIOMETRIKA

Comparison of pancreatic volume and fat amount linked with glucose homeostasis between healthy Caucasians and Koreans

(2018) Eun Roh et al.   DIABETES OBESITY & METABOLISM

The role of triglyceride glucose index in development of Type 2 diabetes mellitus

(2018) Serena Low et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals

(2018) Elfriede Agyemang et al.   JOURNAL OF INFECTIOUS DISEASES

Evaluating surrogate marker information using censored data

(2017) Layla Parast et al.   STATISTICS IN MEDICINE

Triglyceride–glucose index (TyG index) in comparison with fasting plasma glucose improved diabetes prediction in patients with normal fasting glucose: The Vascular-Metabolic CUN cohort

(2016) David Navarro-González et al.   PREVENTIVE MEDICINE

Robust estimation of the proportion of treatment effect explained by surrogate marker information

(2015) Layla Parast et al.   STATISTICS IN MEDICINE

Surrogacy marker paradox measures in meta-analytic settings

(2014) M. R. Elliott et al.   BIOSTATISTICS

Surrogate Measures and Consistent Surrogates

(2013) Tyler J. VanderWeele   BIOMETRICS

Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal

(2013) A. S. C. Conlon et al.   BIOSTATISTICS

Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials

(2010) Julian Wolfson et al.   BIOMETRICS